Pharmaceutical interventions to improve safety of chemotherapy-treated cancer patients: A cross-sectional study

Abstract

Purpose

Cancer chemotherapy is a high-risk process. To improve patient safety, a systematic pharmaceutical analysis of chemotherapy prescriptions is performed in our institution. The aim of this study was to assess the impact of pharmaceutical interventions (PIs) on the safety of patient chemotherapy prescriptions.

Methods

This prospective cross-sectional study was conducted in an 800-bed university hospital with oncology departments. All chemotherapy prescriptions were included and PIs were collected prospectively during one month. The clinical impact of PIs was scored by an expert panel of oncologists and pharmacists, using the Hatoum scale. Univariate and multivariate analysis were conducted to identify factors associated with a higher frequency of PIs.

Results

Of 1346 prescriptions included, 129 required a PI (9.6% (95% CI: 8.1–11.4)). Most PIs were scored as having at least a significant impact for patient safety (69.8% (95% CI: 60.4–76.9)). The frequency of PIs was significantly associated with tumour site (p = 0.04) and weekday of prescription (p = 0.005). Multivariate analysis identified factors independently associated with PI performance, including pancreas and biliary tract cancers (odds ratio = 2.8 (95% CI: 1.4–5.3)), ovary cancers (odds ratio = 2.4 (95% CI: 1.2–4.8)) and head and neck cancers (odds ratio = 2.4 (95% CI: 1.1–5.1)) and the day 1 of the protocol with a cytotoxic agent (odds ratio = 3.7 (95% CI: 1.1–11.1)).

Conclusions

Oncology pharmacists have a critical role in the safety of chemotherapy prescriptions. The coordination between healthcare professionals and access to patient data seem essential to improve the PIs' relevance and their clinical impact on patient safety.

Keywords

Pharmaceutical interventions patient safety chemotherapy medication errors

Get full access to this article

View all access options for this article.

References

Reilly

Bruner

Mitchell

et al.

A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. Support Care Cancer 2013; 21: 1525–1550.

Institute for Safe Medication Practices. ISMP's high-alert medications list, www.ismp.org/assessments/high-alert-medications (accessed 4 March 2018).

Philips

Beam

Brinker

et al.

Retrospective analysis of mortalities associated with medication error. Am Health System Pharm 2001; 58: 1834–1835.

Garrouste-Orgeas

Philippart

Bruel

et al.

Overview of medical errors and adverse events. Ann Intensive Care 2012; 2: 2.

Brennan

Leape

Laird

et al.

Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. 1991. Qual Saf Health Care 2004; 13: 145–151.

Choi

Lee

S-M

Flynn

et al.

Incidence and treatment costs attributable to medication errors in hospitalized patients. Res Social Adm Pharm 2016; 12: 428–437.

Kaushal

Bates

Franz

et al.

Costs of adverse events in intensive care units. Crit Care Med 2007; 35: 2479–2483.

De Vries

Ramrattan

Smorenburg

et al.

The incidence and nature of in-hospital adverse events: a systematic review. Qual Saf Health Care 2008; 17: 216–223.

Kohn

Corrigan

Donaldson

. Institute of Medicine (US) Committee on Quality of Health Care in America. To err is human: building a safer health system, Washington: National Academies Press, 2000.

10.

National Coordinating Council for Medication Error Reporting and Prevention. About medication errors: what is a medication error?, www.nccmerp.org/about-medication-errors (accessed 4 March 2018).

11.

Scotté

Oudard

Aboudagga

et al.

A practical approach to improve safety and management in chemotherapy units based on the PROCHE – programme for optimisation of the chemotherapy network monitoring program. Eur J Cancer 2013; 49: 541–544.

12.

Allenet

Bedouch

Rose

et al.

Validation of an instrument for the documentation of clinical pharmacists' interventions. Pharm World Sci 2006; 28: 181–188.

13.

Hatoum

Hutchinson

Witte

et al.

Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm 1988; 22: 252–259.

14.

Ranchon

Salles

Späth

H-M

et al.

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer 2011; 11: 478.

15.

Knez

Laaksonen

Duggan

. Evaluation of clinical interventions made by pharmacists in chemotherapy preparation. Radiol Oncol 2010; 44: 249–256.

16.

Basch

Deal

Dueck

et al.

Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 2017; 318: 197–198.

17.

Slama

Jerome

Jacquot

et al.

Prescription errors with cytotoxic drugs and the inadequacy of existing classifications. Pharm World Sci PWS 2005; 27: 339–343.

18.

Vantard

Ranchon

Schwiertz

et al.

EPICC study: evaluation of pharmaceutical intervention in cancer care. J Clin Pharm Ther 2015; 40: 196–203.

19.

Shamliyan

Duval

et al.

Just what the doctor ordered. Review of the evidence of the impact of computerized physician order entry system on medication errors. Health Serv Res 2008; 43: 32–53.

20.

Aita

Belvedere

De Carlo

et al.

Chemotherapy prescribing errors: an observational study on the role of information technology and computerized physician order entry systems. BMC Health Serv Res 2013; 13: 522.

21.

Womer

Tracy

Soo-Hoo

et al.

Multidisciplinary systems approach to chemotherapy safety: rebuilding processes and holding the gains. J Clin Oncol 2002; 20: 4705–4712.

22.

Gandhi

Bartel

Shulman

et al.

Medication safety in the ambulatory chemotherapy setting. Cancer 2005; 104: 2477–2483.

23.

Nerich

Limat

Demarchi

et al.

Computerized physician order entry of injectable antineoplastic drugs: an epidemiologic study of prescribing medication errors. Int J Med Inf 2010; 79: 699–706.

24.

Markert

Thierry

Kleber

et al.

Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment. Int J Cancer 2009; 124: 722–728.

25.

Footracer

. Alert fatigue in electronic health records. JAAPA 2015; 28: 41–42.